(Q36219713)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

main subject

squamous cell carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Susanne J Rogers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Kevin J Harrington

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Chris Nutting

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Peter Rhys-Evans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Suzanne A Eccles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

English

0 references

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

769-790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16083342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Focus on head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Epidemiology of head and neck cancer: magnitude of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

State-of-the-art management of locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Clinical use of intensity-modulated radiotherapy: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Why do patients with head and neck squamous cell carcinoma experience distant metastases: can they be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Integrin-linked kinase: a cancer therapeutic target unique among its ILK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Focal adhesion kinase: in command and control of cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Biological significance of c-erbB family oncogenes in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Oncogenes and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Identification of tyrosine kinases overexpressed in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Integrin signalling during tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Interactions between growth factor receptors and adhesion molecules: breaking the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Control of adhesion-dependent cell survival by focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

FAK integrates growth-factor and integrin signals to promote cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Regulation of tumor angiogenesis by integrin-linked kinase (ILK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Chemokines in neoplastic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Investigation of CXCR4 in squamous cell carcinoma of the tongue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

CXC chemokines in angiogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Hypoxia-inducible factor-1 and oncogenic signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Functional roles of Akt signaling in mouse skin tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Targets and mechanisms for the regulation of translation in malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Signaling intricacies take center stage in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

21 January 2018

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Signaling pathways responsible for cancer cell invasion as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Angiogenesis and signal transduction in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Akt and Ca2+ signaling in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Akt, protein kinase C, and mitogen-activated protein kinase phosphorylation status in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Novel therapeutic targets in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Predictors of the response to gefitinib in refractory non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Targeting key steps in metastatic tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The Akt pathway: molecular targets for anti-cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phosphoinositide 3-kinases as targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Selective role of PI3K delta in neutrophil inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Identification of novel effectors of invasive cell growth downstream of phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Targeting the gatekeeper residue in phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

AKT/PKB signaling mechanisms in cancer and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Therapeutic potential of target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Cancer: survival pathways meet their end.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Will mTOR inhibitors make it as cancer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Gene profiling in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769

Structural insights into phosphoinositide 3-kinase catalysis and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.4.769